Metformin News and Research RSS Feed - Metformin News and Research

Metformin is the active ingredient in a drug used to treat diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. It decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body’s use of the glucose. Metformin is a type of antidiabetic agent.
MicroBiome Therapeutics' NM 505 drug can improve tolerability of metformin

MicroBiome Therapeutics' NM 505 drug can improve tolerability of metformin

MicroBiome TherapeuticsTM LLC, today reported positive topline results from a proof of concept study testing whether its investigational drug, NM 505, can improve the tolerability of metformin, the first-line therapy for Type 2 diabetes worldwide. [More]
Treating prediabetes patients could help prevent severe complications associated with diabetes

Treating prediabetes patients could help prevent severe complications associated with diabetes

Doctors at three leading research institutions and the American Diabetes Association report that treating patients with prediabetes as if they had diabetes could help prevent or delay the most severe complications associated with this chronic disease, which affects about thirty million people in the United States. [More]
AMPK gene can slow aging process when activated remotely in key organ systems

AMPK gene can slow aging process when activated remotely in key organ systems

UCLA biologists have identified a gene that can slow the aging process throughout the entire body when activated remotely in key organ systems. [More]
Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

Jardiance (empagliflozin) tablets are now available by prescription in pharmacies across the United States, including Walgreens, Rite Aid, Kroger and many other leading chain and independent retailers, according to Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company. [More]
Patients treated with drug for type 2 diabetes can live longer than people without the condition

Patients treated with drug for type 2 diabetes can live longer than people without the condition

Patients treated with a drug widely prescribed for type 2 diabetes can live longer than people without the condition, a large-scale study involving over 180,000 people has shown. [More]
New, promising approach combines metformin and SGLT2 inhibitors to treat diabetes

New, promising approach combines metformin and SGLT2 inhibitors to treat diabetes

Various active substances in oral antidiabetic agents are frequently combined in the treatment of diabetes in order to achieve an effective reduction in the blood sugar. A new, very promising approach combines the substances metformin and SGLT2 inhibitors, the latter were just approved in 2012. [More]

Metformin and SGLT2 inhibitors together reduce blood sugar levels

Metformin and SGLT2 inhibitors together reduce the blood sugar levels considerably more effectively than either drug alone. [More]
EMA CHMP issues positive opinion for label updates to Takeda's Vipidia, Vipdomet and Incresync

EMA CHMP issues positive opinion for label updates to Takeda's Vipidia, Vipdomet and Incresync

Takeda Pharmaceuticals International GmbH today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued positive opinions for updates to the Summary of Product Characteristics (SmPC) for Vipidia (alogliptin) and the fixed-dose combination (FDC) therapies Vipdomet (alogliptin and metformin) and Incresync (alogliptin and pioglitazone). [More]
Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson today announced sales of $19.5 billion for the second quarter of 2014, an increase of 9.1% as compared to the second quarter of 2013. Operational results increased 9.4% and the negative impact of currency was 0.3%. [More]
Labelling people as pre-diabetic is drastically premature measure with no medical value

Labelling people as pre-diabetic is drastically premature measure with no medical value

Labelling people with moderately high blood sugar as pre-diabetic is a drastically premature measure with no medical value and huge financial and social costs, say researchers from UCL and the Mayo Clinic, Minnesota. [More]
Medical treatment guidelines for diabetes

Medical treatment guidelines for diabetes

Medical treatment guidelines are suggestions that international organizations such as the American Diabetes Association, the European Society for the Study of Diabetes and the American Association of Clinical Endocrinologists, used to set the tone in the control of the disease and how to apply a better therapy, depending on the physical condition of the person. [More]
Continuation of metformin after cirrhosis diagnosis improves survival rates in diabetes patients

Continuation of metformin after cirrhosis diagnosis improves survival rates in diabetes patients

Researchers at Mayo Clinic released a new study reversing current thought on the treatment of cirrhotic patients with type 2 diabetes. [More]
Mayo Clinic study: Reversing current thought on treatment of cirrhotic patients with type 2 diabetes

Mayo Clinic study: Reversing current thought on treatment of cirrhotic patients with type 2 diabetes

Researchers at Mayo Clinic released a new study reversing current thought on the treatment of cirrhotic patients with type 2 diabetes. The study found that the continuation of metformin after a cirrhosis diagnosis improved survival rates among diabetes patients. [More]
U of MD researchers to use $3.7 million NIH grant to develop novel method to treat monogenic diabetes

U of MD researchers to use $3.7 million NIH grant to develop novel method to treat monogenic diabetes

The National Institutes of Health has awarded a four-year, $3.7 million grant to researchers at the University of Maryland School of Medicine to develop a personalized medicine program to help doctors diagnose and treat monogenic diabetes - a form of diabetes caused by a mutation in a single gene. [More]
Type 2 diabetes Patients who take metformin plus insulin at higher risk for heart disease, death

Type 2 diabetes Patients who take metformin plus insulin at higher risk for heart disease, death

Patients with type 2 diabetes who take a combination of metformin plus insulin may be at higher risk for cardiovascular disease and death compared with those who take a combination of metformin plus sulfonylurea, according to a new study funded by the Agency for Healthcare Research and Quality that appears in the June 11 issue of JAMA. [More]
Researchers discover strong genetic risk factor for type 2 diabetes in Latin American patients

Researchers discover strong genetic risk factor for type 2 diabetes in Latin American patients

In the largest study of its kind published to date, an international team of researchers in Mexico and the United States has discovered a strong genetic risk factor for type 2 diabetes that primarily affects Latin American patients, but is rare elsewhere. [More]
FDA grants orphan drug designation to EffRx Pharmaceuticals' EX404 for treatment of PCOS

FDA grants orphan drug designation to EffRx Pharmaceuticals' EX404 for treatment of PCOS

EffRx Pharmaceuticals SA, a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to its proprietary metformin-based product candidate, EX404, for the treatment of pediatric polycystic ovary syndrome (PCOS). [More]
Metformin drug slows ageing and increases lifespan

Metformin drug slows ageing and increases lifespan

A study by Belgian doctoral researcher Wouter De Haes (KU Leuven) and colleagues provides new evidence that metformin, the world's most widely used anti-diabetic drug, slows ageing and increases lifespan. [More]
NCI awards 'provocative questions' grants to Jackson lab researchers

NCI awards 'provocative questions' grants to Jackson lab researchers

Jackson Laboratory Assistant Professors Jennifer Trowbridge, Ph.D., and Chengkai Dai, M.D., Ph.D., have each received new federal research grants through a funding mechanism designed to address "provocative questions" about cancer set out by the National Cancer Institute (NCI). [More]
Commonly used diabetes medications may also have positive effects against cancer cell proliferation

Commonly used diabetes medications may also have positive effects against cancer cell proliferation

One of the most commonly used medications to control diabetes may also have positive effects against cancer cell proliferation, as show in research done at the Center for Research and Advanced Studies (CINVESTAV) in Mexico. [More]